

INTERVENTIONAL  
VASCULAR  
DIAGNOSTICS AND  
THERAPY

# SeQuent<sup>®</sup> Please OTW

PERIPHERAL DRUG COATED BALLOON CATHETER

NOW AVAILABLE 0.018" VERSION

# SeQuent<sup>®</sup> Please OTW

PERIPHERAL DRUG COATED BALLOON CATHETER

## The next level in treating peripheral stenoses

Following a path of sustained research and development in drug coated balloons SeQuent<sup>®</sup> Please OTW offers significant improvements in peripheral angioplasty.<sup>1</sup>

### DCB TREATMENT FOR ABOVE AND BELOW THE KNEE

- Leave nothing behind
- Effective and homogeneous drug delivery into the vessel wall
- Long-term efficacy with short-term drug release
- Keep all therapeutical options
- No stent related complications

### Paclitaxel with an effective drug dose of 3µg/mm<sup>2</sup>

- Effective drug dose in comparison to DCB with lower drug concentration<sup>2</sup>
- Homogeneous coating even in the balloon folds

<sup>1</sup> A Tepe, G. et al. Cardiovasc Intervent Radiol (2017). doi:10.1007/s00270-017-1713-2.

<sup>2</sup> "...standard dose (3.0-µg and 3.5µg) PCBs were significantly more effective compared with low-dose 2µg PCB in reducing both restenosis [...] and TLR [...]." Katsanos K et al. in J Endovasc Ther. 2016 Apr;23(2):356-70.

<sup>3</sup> Data on file at B.Braun



## A fruitful formulation: Paclitaxel & Resveratrol

SeQuent® Please OTW with its optimized and clinically proven<sup>1</sup> coating technology is made to facilitate easy and effective DCB use in daily practice.

### Resveratrol as hydrophilic excipient

---

- Naturally occurring, plant based substance found e.g. in red grapes & raspberries.
- Acts as hydrophilic spacer and makes Paclitaxel bioavailable
- Enables drug transfer into vessel wall

### Consistent crystalline coating for your daily routine<sup>3</sup>

---

- High mechanical resistance of the coating
- Low drug loss in simulated use (<2%)
- Highly available drug dose after inflation


# SeQuent<sup>®</sup> Please OTW

CONSEQUENT RCT

## CONSEQUENT Randomized Controlled Trial<sup>4</sup>

### Study design & characteristics

- 153 patients
- Rutherford II-IV (95% Grade III-IV)
- Pre-procedure diameter stenosis: 76.6 % ( $\pm$ 18.1)
- TASC C+D lesions: 23.5 %
- Mean lesion length: 13.2 cm ( $\pm$ 10.4)
- Positive Remodeling (LLL <0.00mm) DCB group: 35.2 %
- Predilatation: 55.6 %<sup>5</sup>
- Bailout stenting: 16.3 %



<sup>4</sup> Albrecht T et al. Cardiovasc Intervent Radiol. 2018 Jul;41(7):1008-1014.

<sup>5</sup> Predilatation was only mandatory in total occlusions and even long & complex lesions were treated.


<sup>6</sup> Schroder H Catheterization and Cardiovascular Interventions, Volume 86, Issue 2 August 2015 Pages 278-286.

<sup>7</sup> Werk M et al. Circ Cardiovasc Interv. 2012;5(6):831-840.

<sup>8</sup> Scheinert D et al. JACC Cardiovasc Interv. 2014;7(1):10-19.

<sup>9</sup> Zeller T et al. JACC Cardiovasc Interv. 2015;8(12):1614-1622.

The safety and efficacy of SeQuent® Please OTW was investigated in real world lesion morphologies.






**NO FURTHER TLR  
AFTER ONE YEAR**

# SeQuent<sup>®</sup> Please OTW


CONSEQUENT RCT

## Improving patients' quality of life

The CONSEQUENT randomized controlled trial demonstrated outstanding quality of life improvements for patients treated with SeQuent<sup>®</sup> Please OTW<sup>4\*</sup>.



<sup>4\*</sup> reference see page 4



# SeQuent<sup>®</sup> Please OTW

## PRODUCT PORTFOLIO AND SPECIFICATIONS

### SeQuent<sup>®</sup> Please OTW 035

Shaft length 75 cm	Shaft length 130 cm	Balloon diameter (mm)	Balloon length (mm)	Sheath compatibility (F)	Nominal pressure (atm)	Rated burst pressure (atm)
35040040	35340040	4.0	40	5	6	16
35140060	35340060	4.0	60	5	6	16
35140080	35340080	4.0	80	5	6	15
35140120	35340120	4.0	120	5	6	15
35140150	35340150	4.0	150	5	6	15
35150040	35350040	5.0	40	6	6	14
35150060	35350060	5.0	60	6	6	14
35150080	35350080	5.0	80	6	6	13
35150120	35350120	5.0	120	6	6	13
35150150	35350150	5.0	150	6	6	13
35160040	35360040	6.0	40	6	6	13
35160060	35360060	6.0	60	6	6	13
35160080	35360080	6.0	80	6	6	12
35160120	35360120	6.0	120	6	6	12
35160150	35360150	6.0	150	6	6	12
35170040		7.0	40	6	6	12
35170060		7.0	60	6	6	12
35180040		8.0	40	6	6	12
35180060		8.0	60	6	6	12



### Technical specifications

Catheter type	OTW	Coating	Drug: Paclitaxel (concentration 3 µg/mm <sup>2</sup> )
Shaft profile	035: 4.9F – 5.4F 018: 3.6F – 3.9F 014: 2.5F – 3.6F		Excipient: Resveratrol (plant based substance acts as hydrophilic spacer)
Lesion entry profile	035: 0.041" – 0.051" 018: 0.021" – 0.032" 014: 0.018"		Homogeneous coating even in the balloon folds exceeding distal and proximal markers
Radiopaque markers	2 markers (Platinum/Iridium)		Duration of inflated balloon: ≥ 30 seconds

NEW 0.018"

## SeQuent® Please OTW 018

Shaft length 75 cm	Shaft length 130 cm	Balloon diameter (mm)	Balloon length (mm)	Sheath compatibility (F)	Nominal pressure (atm)	Rated burst pressure (atm)
	18220040	2.0	40	4	6	16
	18220080	2.0	80	4	6	15
	18220120	2.0	120	4	6	15
	18225040	2.5	40	4	6	16
	18225080	2.5	80	4	6	15
	18225120	2.5	120	4	6	15
	18230040	3.0	40	4	6	16
	18230080	3.0	80	4	6	15
	18230120	3.0	120	4	6	15
18135040	18235040	3.5	40	4	6	16
18135080	18235080	3.5	80	4	6	15
18135120	18235120	3.5	120	4	6	15
18140040	18240040	4.0	40	4	6	16
18140060	18240060	4.0	60	4	6	16
18140080	18240080	4.0	80	4	6	15
18140120	18240120	4.0	120	4	6	15
18150040	18250040	5.0	40	5	6	14
18150060	18250060	5.0	60	5	6	14
18150080	18250080	5.0	80	5	6	13
18150120	18250120	5.0	120	5	6	13
18160040	18260040	6.0	40	5	6	14
18160060	18260060	6.0	60	5	6	14
18160080	18260080	6.0	80	5	6	12
18160120	18260120	6.0	120	5	6	12


## SeQuent® Please OTW 014

	Shaft length 130 cm	Balloon diameter (mm)	Balloon length (mm)	Sheath compatibility (F)	Nominal pressure (atm)	Rated burst pressure (atm)
	14215040	1.5	40	4	6	16
	14215080	1.5	80	4	6	16
	14215120	1.5	120	4	6	16
	14220040	2.0	40	4	6	16
	14220080	2.0	80	4	6	15
	14220120	2.0	120	4	6	15
	14220150	2.0	150	4	6	15
	14225040	2.5	40	4	6	16
	14225080	2.5	80	4	6	15
	14225120	2.5	120	4	6	15
	14225150	2.5	150	4	6	15
	14230040	3.0	40	4	6	16
	14230080	3.0	80	4	6	15
	14230120	3.0	120	4	6	15
	14230150	3.0	150	4	6	15



# B. Braun Vascular Systems

PORTFOLIO FOR PERIPHERAL DIAGNOSTICS AND THERAPY



Angiodyn® Procedure Kits



Celsite® Access Port Systems



Vascular Implants

B. Braun Melsungen AG | Vascular Systems | Sieversufer 8 | 12359 Berlin | Germany  
Phone +49 30 568207-300 | Fax +49 30 568207-210 | [www.bbraun.com](http://www.bbraun.com)

Manufacturer acc. to MDD 93/42EG: B. Braun Melsungen AG, 34212 Melsungen, Germany

The product trademarks "SeQuent", "VascuFlex", "Angiodyn" and "Celsite" are registered trademarks of B. Braun Melsungen AG.

Subject to technical changes. All rights reserved. This brochure may only be used for the exclusive purpose of obtaining information about our products. Reproduction in any form partial or otherwise is not permitted.